[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists
- PMID: 16165125
- DOI: 10.1016/j.ejphar.2005.08.008
[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists
Abstract
Alvimopan is a novel peripheral micro opioid antagonist in clinical development for the management of post-operative ileus and opioid-induced bowel dysfunction. We hypothesized that the long duration of action of alvimopan might be related to a slower dissociation rate from the micro opioid receptor compared to other shorter acting antagonists. The dissociation rate of alvimopan from the micro opioid receptor (t(1/2)=30--44 min) was comparable to that of the long acting partial agonist buprenorphine (t(1/2)=44 min), but was slower than those of the antagonists naloxone (t(1/2)=0.82 min) and N-methylnaltrexone (t(1/2)=0.46 min). Also, increases in the apparent affinities and potencies of buprenorphine and alvimopan, but not of naloxone and methylnaltrexone, were observed upon preincubation with the micro opioid receptor. Consistent with its long duration of action, alvimopan has a slow dissociation rate from the micro opioid receptor compared to other shorter acting antagonists and may be more potent if administered prior to dosing with exogenous opioids.
Similar articles
-
The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17340127
-
Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.Eur J Pharmacol. 2004 Sep 19;499(1-2):107-16. doi: 10.1016/j.ejphar.2004.07.097. Eur J Pharmacol. 2004. PMID: 15363957
-
LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.Eur J Pharmacol. 2008 Apr 28;584(2-3):306-11. doi: 10.1016/j.ejphar.2008.02.028. Epub 2008 Feb 19. Eur J Pharmacol. 2008. PMID: 18353307
-
Alvimopan (Adolor/GlaxoSmithKline).Curr Opin Investig Drugs. 2002 Oct;3(10):1496-501. Curr Opin Investig Drugs. 2002. PMID: 12431026 Review.
-
Preclinical studies of opioids and opioid antagonists on gastrointestinal function.Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:46-53. doi: 10.1111/j.1743-3150.2004.00555.x. Neurogastroenterol Motil. 2004. PMID: 15357851 Review.
Cited by
-
Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest.Front Psychiatry. 2024 Jun 17;15:1399803. doi: 10.3389/fpsyt.2024.1399803. eCollection 2024. Front Psychiatry. 2024. PMID: 38952632 Free PMC article.
-
Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.MedComm (2020). 2022 Jun 22;3(3):e148. doi: 10.1002/mco2.148. eCollection 2022 Sep. MedComm (2020). 2022. PMID: 35774845 Free PMC article. Review.
-
Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.J Pharm Pract. 2018 Dec;31(6):658-669. doi: 10.1177/0897190017732263. Epub 2017 Sep 25. J Pharm Pract. 2018. PMID: 28946783 Free PMC article. Review.
-
American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time.J Med Toxicol. 2024 Jan;20(1):64-67. doi: 10.1007/s13181-023-00981-z. Epub 2023 Nov 30. J Med Toxicol. 2024. PMID: 38032431 Free PMC article. No abstract available.
-
Synthetic opioids have disrupted conventional wisdom for treating opioid overdose.Drug Alcohol Depend Rep. 2024 Aug 13;12:100268. doi: 10.1016/j.dadr.2024.100268. eCollection 2024 Sep. Drug Alcohol Depend Rep. 2024. PMID: 39262668 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources